Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

Clinical data show 67% of U.S. patients stayed on imetelstat at 6 months post-launch.

What the company is saying

Geron Corporation is highlighting new real-world and clinical trial data for imetelstat (RYTELO) in lower-risk myelodysplastic syndromes (LR-MDS), presented at major hematology conferences in Japan and Europe. The company emphasizes the breadth of evidence supporting imetelstat, including both U.S. real-world claims data and clinical outcomes from Korean and European cohorts. Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer, frames the narrative around growing global scientific engagement and the opportunity to expand imetelstat's reach. The announcement underscores that most U.S. patients in the real-world cohort started imetelstat in the third line or later, with significant comorbidity, yet a majority remained on therapy at six months. Geron stresses that RYTELO is the first and only telomerase inhibitor approved by both the U.S. FDA and European Commission for this indication. The company positions imetelstat as a first-in-class therapy with potential disease-modifying effects, while also referencing ongoing efforts to expand awareness and market reach.

What the data suggests

The U.S. real-world study included 58 adults with MDS who initiated imetelstat between June 2024 and August 2025, with a mean age of 75 years at diagnosis. Most patients (71%) began imetelstat in the third line or later, and the mean Charleson Comorbidity Index at initiation was 2.6, indicating a substantial comorbidity burden. Despite this, approximately 67% of patients remained on imetelstat therapy at six months, based on Kaplan-Meier estimates. In the Korean cohort, two patients achieved over one year of red blood cell transfusion independence, and among 13 patients from the Phase 2/3 and QTc substudy, early cytopenias were associated with better clinical outcomes, though no quantitative rates or statistical measures are provided. Both long-term Korean responders experienced grade 3/4 neutropenia and thrombocytopenia early in treatment, resolving to grade ≤2 in less than four weeks. The European presentation integrates molecular findings and suggests that transient cytopenias may be an on-target effect and potentially predictive of better response, but again, no numerical efficacy or safety data are disclosed for these associations. RYTELO is approved in the U.S. and EU for transfusion-dependent LR-MDS patients, but the announcement does not include any commercial, revenue, or patient uptake figures.

Analysis

The announcement is generally positive in tone, highlighting new real-world and clinical trial data for imetelstat (RYTELO) in lower-risk myelodysplastic syndromes, as well as regulatory approvals in the United States and European Union. The measurable progress is supported by specific patient cohort sizes, treatment timelines, and a 67% 6-month therapy continuation rate in the U.S. cohort. However, several claims—such as imetelstat potentially altering disease biology, cytopenias being predictive of better response, and improved health-related outcomes—are forward-looking or speculative, lacking quantitative evidence or statistical support in the disclosed data. The announcement does not include any financial, revenue, or commercial performance metrics, so the investment signal is limited to clinical and regulatory progress. There is no indication of a large capital outlay or long-dated, uncertain returns in this release. The gap between narrative and evidence is moderate, with some claims inflated by suggestive language not fully backed by disclosed outcomes.

Risk flags

• ●The announcement lacks quantitative efficacy and safety outcomes for several claims, particularly for the Korean and European cohorts, making it difficult to independently assess the magnitude of clinical benefit or risk.
• ●Forward-looking statements about imetelstat potentially altering disease biology and the predictive value of early cytopenias are not supported by statistical evidence or mechanistic data in this release, introducing uncertainty about the generalizability of these findings.
• ●No commercial performance metrics, such as revenue, patient uptake, or market penetration, are disclosed, so the financial impact and adoption trajectory of RYTELO remain unclear for investors.

Bottom line

Geron provides new clinical and real-world data supporting imetelstat's use in lower-risk myelodysplastic syndromes, with 67% of U.S. patients remaining on therapy at six months and approvals in both the U.S. and EU. While the company emphasizes potential disease-modifying effects and manageable safety, most efficacy and safety claims for non-U.S. cohorts are qualitative and lack supporting statistics. The absence of commercial or financial data means investors cannot gauge the market impact or revenue trajectory from this update. The most actionable takeaway is that imetelstat is being used in real-world settings with a majority of patients persisting on therapy through six months, despite high comorbidity. Investors should watch for future disclosures with quantitative efficacy, safety, and commercial metrics to better assess the drug's long-term value and market performance.

Announcement summary

(NASDAQ:GERN) Geron Corporation announced two oral presentations and one poster presentation on imetelstat in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the 88th Annual Meeting of the Japanese Society of Hematology and the 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology. The presentations included real-world evidence and findings from the Phase 3 IMerge trial. Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron, stated that the presentations provide an opportunity to share evidence relevant to patient populations across regions and to engage with clinicians. The retrospective U.S. real-world study (N=58, mean age 75 years at diagnosis) used Komodo Health database claims data for adults with MDS who initiated imetelstat between June 2024 and August 2025, representing the first 14 months after the U.S. launch. Most patients (71%) started imetelstat in the third line or later, with a mean Charleson Comorbidity Index of 2.6 at initiation. Despite substantial comorbidity burden, approximately 67% of patients remained on therapy at 6 months (Kaplan-Meier estimate). A post-hoc study in Korean patients with LR-MDS included two patients with over one year of red blood cell transfusion independence (RBC-TI) on imetelstat, and 13 patients from the Phase 2/3 and QTc substudy of IMerge. Both long-term responders experienced grade 3/4 neutropenia and thrombocytopenia early in treatment, which resolved to grade ≤2 in less than 4 weeks. Durable efficacy and manageable safety were observed in Korean patients across a range of characteristics. Early cytopenias with imetelstat were associated with better clinical outcomes in the 13 Korean patients, consistent with prior IMerge data. The German, Austrian and Swiss Societies meeting presentation integrated molecular findings, cytopenias, and clinical outcomes from the Phase 2/3 and QTc substudy of IMerge, including evidence suggesting imetelstat may potentially alter the underlying biology of LR-MDS. Transient cytopenias early in treatment may be an on-target effect and predictive of better therapeutic response. Certain patients with LR-MDS and transfusion-dependent anemia who achieve sustained RBC-TI (≥8-week, ≥24-week, or ≥1-year) with imetelstat may experience improved health-related outcomes, including fatigue and QUALMS scores. RYTELO (imetelstat) is approved in the United States for adult patients with LR-MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or are ineligible for erythropoiesis-stimulating agents. RYTELO is also approved in the European Union for adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. RYTELO is administered as an intravenous infusion over two hours every four weeks. RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission. The presentations are available on the Publications & Presentations page of the Geron website.

Disagree with this article?